Miles P Davenport

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4670148/publications.pdf

Version: 2024-02-01

222 papers 15,835 citations

25034 57 h-index 26613 107 g-index

248 all docs

248 docs citations

times ranked

248

19963 citing authors

#	Article	IF	CITATIONS
1	Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe, The, 2022, 3, e52-e61.	7.3	436
2	Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial. Clinical Infectious Diseases, 2022, 75, e878-e879.	5.8	20
3	Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design. Journal of Infectious Diseases, 2022, 226, 236-245.	4.0	2
4	Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature, 2022, 602, 654-656.	27.8	928
5	Similarly efficacious anti-malarial drugs SJ733 and pyronaridine differ in their ability to remove circulating parasites in mice. Malaria Journal, 2022, 21, 49.	2.3	2
6	Establishment and recall of SARS-CoV-2 spike epitope-specific CD4+ T cell memory. Nature Immunology, 2022, 23, 768-780.	14.5	41
7	Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. Cell, 2022, 185, 1875-1887.e8.	28.9	148
8	Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?. Nature Reviews Immunology, 2022, 22, 387-397.	22.7	93
9	The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants. Immunity, 2022, 55, 1316-1326.e4.	14.3	38
10	Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia. Nature Microbiology, 2022, 7, 896-908.	13.3	32
11	Parasite Viability as a Measure of <i>In Vivo</i> Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment. Antimicrobial Agents and Chemotherapy, 2022, 66, .	3.2	3
12	Parasite Viability as a Superior Measure of Antimalarial Drug Activity in Humans. Journal of Infectious Diseases, 2021, 223, 2154-2163.	4.0	10
13	Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nature Communications, 2021, 12, 1162.	12.8	316
14	Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	109
15	Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nature Reviews Immunology, 2021, 21, 395-404.	22.7	223
16	CD8+ T cells fail to limit SIV reactivation following ART withdrawal until after viral amplification. Journal of Clinical Investigation, 2021, 131, .	8.2	18
17	Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine, 2021, 27, 1205-1211.	30.7	3,133
18	Decay of Fc-dependent antibody functions after mild to moderate COVID-19. Cell Reports Medicine, 2021, 2, 100296.	6.5	56

#	Article	IF	CITATIONS
19	Transient viral replication during analytical treatment interruptions in SIV infected macaques can alter the rebound-competent viral reservoir. PLoS Pathogens, 2021, 17, e1009686.	4.7	7
20	Immune imprinting and SARS-CoV-2 vaccine design. Trends in Immunology, 2021, 42, 956-959.	6.8	73
21	Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain. Cell Reports, 2021, 37, 109822.	6.4	35
22	mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science, 2021, 374, abm0829.	12.6	609
23	Anti-Drug Antibodies in Pigtailed Macaques Receiving HIV Broadly Neutralising Antibody PGT121. Frontiers in Immunology, 2021, 12, 749891.	4.8	4
24	The mucosal barrier and anti-viral immune responses can eliminate portions of the viral population during transmission and early viral growth. PLoS ONE, 2021, 16, e0260010.	2.5	1
25	Tear antibodies to SARSâ€CoVâ€2: implications for transmission. Clinical and Translational Immunology, 2021, 10, e1354.	3.8	15
26	Genetically barcoded SIV reveals the emergence of escape mutations in multiple viral lineages during immune escape. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 494-502.	7.1	9
27	Transcriptome dynamics of CD4+ T cells during malaria maps gradual transit from effector to memory. Nature Immunology, 2020, 21, 1597-1610.	14.5	43
28	Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nature Medicine, 2020, 26, 1428-1434.	30.7	400
29	Artemisinin Resistance and the Unique Selection Pressure of a Short-acting Antimalarial. Trends in Parasitology, 2020, 36, 884-887.	3.3	19
30	Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. Nature Reviews Immunology, 2020, 20, 727-738.	22.7	107
31	Stochastic Expansions Maintain the Clonal Stability of CD8+ T Cell Populations Undergoing Memory Inflation Driven by Murine Cytomegalovirus. Journal of Immunology, 2020, 204, 112-121.	0.8	21
32	Building a T cell compartment: how immune cell development shapes function. Nature Reviews Immunology, 2020, 20, 499-506.	22.7	51
33	Fc functional antibody responses to adjuvanted versus unadjuvanted seasonal influenza vaccination in community-dwelling older adults. Vaccine, 2020, 38, 2368-2377.	3.8	10
34	Malaria Parasite Clearance: What Are We Really Measuring?. Trends in Parasitology, 2020, 36, 413-426.	3.3	21
35	Impact of fluctuation in frequency of human immunodeficiency virus/simian immunodeficiency virus reactivation during antiretroviral therapy interruption. Proceedings of the Royal Society B: Biological Sciences, 2020, 287, 20200354.	2.6	1
36	Moving the HIV vaccine field forward: concepts of protective immunity. Lancet HIV, the, 2019, 6, e406-e410.	4.7	1

#	Article	IF	Citations
37	Interaction between maternally derived antibodies and heterogeneity in exposure combined to determine time-to-first Plasmodium falciparum infection in Kenyan infants. Malaria Journal, 2019, 18, 19.	2.3	9
38	Defining early SIV replication and dissemination dynamics following vaginal transmission. Science Advances, 2019, 5, eaav7116.	10.3	30
39	Plasmodium-specific antibodies block in vivo parasite growth without clearing infected red blood cells. PLoS Pathogens, 2019, 15, e1007599.	4.7	20
40	The peripheral differentiation of human natural killer T cells. Immunology and Cell Biology, 2019, 97, 586-596.	2.3	20
41	Fate mapping reveals the age structure of the peripheral T cell compartment. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3974-3981.	7.1	27
42	<i>In Vivo</i> Validation of the Viral Barcoding of Simian Immunodeficiency Virus SIVmac239 and the Development of New Barcoded SIV and Subtype B and C Simian-Human Immunodeficiency Viruses. Journal of Virology, 2019, 94, .	3.4	24
43	Novel RNA viruses associated with Plasmodium vivax in human malaria and Leucocytozoon parasites in avian disease. PLoS Pathogens, 2019, 15, e1008216.	4.7	50
44	Functional cure of HIV: the scale of the challenge. Nature Reviews Immunology, 2019, 19, 45-54.	22.7	93
45	Predictors of SIV recrudescence following antiretroviral treatment interruption. ELife, 2019, 8, .	6.0	18
46	Title is missing!. , 2019, 15, e1008216.		0
47	Title is missing!. , 2019, 15, e1008216.		0
48	Title is missing!. , 2019, 15, e1008216.		0
49	HIV Reactivation after Partial Protection by Neutralizing Antibodies. Trends in Immunology, 2018, 39, 359-366.	6.8	6
50	Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency. Journal of Virology, 2018, 92, .	3.4	12
51	<i>In Silico</i> Investigation of the Decline in Clinical Efficacy of Artemisinin Combination Therapies Due to Increasing Artemisinin and Partner Drug Resistance. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	4
52	Quantification of host-mediated parasite clearance during blood-stage Plasmodium infection and anti-malarial drug treatment in mice. International Journal for Parasitology, 2018, 48, 903-913.	3.1	8
53	Lifelong CMV infection improves immune defense in old mice by broadening the mobilized TCR repertoire against third-party infection. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6817-E6825.	7.1	52
54	Withinâ€host modeling of bloodâ€stage malaria. Immunological Reviews, 2018, 285, 168-193.	6.0	26

#	Article	IF	CITATIONS
55	Developmental Origin Governs CD8+ T Cell Fate Decisions during Infection. Cell, 2018, 174, 117-130.e14.	28.9	132
56	Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques. Journal of Clinical Investigation, 2018, 129, 182-191.	8.2	69
57	Molecularly barcoded Zika virus libraries to probe in vivo evolutionary dynamics. PLoS Pathogens, 2018, 14, e1006964.	4.7	38
58	Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents. Journal of Virology, 2017, 91, .	3.4	21
59	Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption. Journal of Virology, 2017, 91, .	3.4	14
60	Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV. Human Vaccines and Immunotherapeutics, 2017, 13, 2726-2737.	3.3	1
61	Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?. Journal of Virology, 2017, 91, .	3.4	10
62	Characterising the effect of antimalarial drugs on the maturation and clearance of murine blood-stage Plasmodium parasites in vivo. International Journal for Parasitology, 2017, 47, 913-922.	3.1	19
63	A mechanistic model quantifies artemisinin-induced parasite growth retardation in blood-stage Plasmodium falciparum infection. Journal of Theoretical Biology, 2017, 430, 117-127.	1.7	9
64	Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection. Science Translational Medicine, 2017, 9, .	12.4	45
65	Host-mediated impairment of parasite maturation during blood-stage <i>Plasmodium</i> infection. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 7701-7706.	7.1	27
66	Fc functional antibodies in humans with severe H7N9 and seasonal influenza. JCl Insight, 2017, 2, .	5.0	39
67	Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy. PLoS Pathogens, 2017, 13, e1006359.	4.7	77
68	IL-15 promotes activation and expansion of CD8+ T cells in HIV-1 infection. Journal of Clinical Investigation, 2016, 126, 2745-2756.	8.2	97
69	HIV-1 Mutation and Recombination Rates Are Different in Macrophages and T-cells. Viruses, 2016, 8, 118.	3.3	9
70	Estimating the in-vivo HIV template switching and recombination rate. Aids, 2016, 30, 185-192.	2.2	21
71	Modeling the dynamics of neonatal CD8 + Tâ€cell responses. Immunology and Cell Biology, 2016, 94, 838-848.	2.3	24
72	Source of CpG Depletion in the HIV-1 Genome. Molecular Biology and Evolution, 2016, 33, 3205-3212.	8.9	30

#	Article	IF	CITATIONS
73	Modeling of EBV Infection and Antibody Responses in Kenyan Infants With Different Levels of Malaria Exposure Shows Maternal Antibody Decay is a Major Determinant of Early EBV Infection. Journal of Infectious Diseases, 2016, 214, 1390-1398.	4.0	15
74	Defining the Effectiveness of Antimalarial Chemotherapy: Investigation of the Lag in Parasite Clearance Following Drug Administration. Journal of Infectious Diseases, 2016, 214, 753-761.	4.0	13
75	The Neonatal CD8+ T Cell Repertoire Rapidly Diversifies during Persistent Viral Infection. Journal of Immunology, 2016, 196, 1604-1616.	0.8	17
76	Impact of <i>Plasmodium falciparum </i> Coinfection on Longitudinal Epstein-Barr Virus Kinetics in Kenyan Children. Journal of Infectious Diseases, 2016, 213, 985-991.	4.0	40
77	High fidelity simian immunodeficiency virus reverse transcriptase mutants have impaired replication in vitro and in vivo. Virology, 2016, 492, 1-10.	2.4	10
78	Safety and Reproducibility of a Clinical Trial System Using Induced Blood Stage Plasmodium vivax Infection and Its Potential as a Model to Evaluate Malaria Transmission. PLoS Neglected Tropical Diseases, 2016, 10, e0005139.	3.0	39
79	Analysis of the In Vivo Turnover of CD4+ T-Cell Subsets in Chronically SIV-Infected Sooty Mangabeys. PLoS ONE, 2016, 11, e0156352.	2.5	2
80	Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5–8 Days. PLoS Pathogens, 2016, 12, e1005740.	4.7	21
81	Central memory CD4+ T cells are preferential targets of double infection by HIV-1. Virology Journal, 2015, 12, 184.	3.4	5
82	HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Daysâ€"Implications for HIV Remission. PLoS Pathogens, 2015, 11, e1005000.	4.7	92
83	Time-to-infection by Plasmodium falciparum is largely determined by random factors. BMC Medicine, 2015, 13, 19.	5. 5	7
84	Modeling the Dynamics of Plasmodium vivax Infection and Hypnozoite Reactivation In Vivo. PLoS Neglected Tropical Diseases, 2015, 9, e0003595.	3.0	87
85	A general method to eliminate laboratory induced recombinants during massive, parallel sequencing of cDNA library. Virology Journal, 2015, 12, 55.	3.4	14
86	Innate Immunity Induced by Plasmodium Liver Infection Inhibits Malaria Reinfections. Infection and Immunity, 2015, 83, 1172-1180.	2.2	55
87	Epitope-Specific CD8+T Cell Kinetics Rather than Viral Variability Determine the Timing of Immune Escape in Simian Immunodeficiency Virus Infection. Journal of Immunology, 2015, 194, 4112-4121.	0.8	9
88	Reduced erythrocyte susceptibility and increased host clearance of young parasites slows Plasmodium growth in a murine model of severe malaria. Scientific Reports, 2015, 5, 9412.	3.3	15
89	Understanding the Relationship Between <i>Plasmodium falciparum</i> Growth Rate and Multiplicity of Infection. Journal of Infectious Diseases, 2015, 211, 1121-1127.	4.0	25
90	CD161 Defines a Transcriptional and Functional Phenotype across Distinct Human T Cell Lineages. Cell Reports, 2014, 9, 1075-1088.	6.4	264

#	Article	IF	Citations
91	CD4 Depletion in SIV-Infected Macaques Results in Macrophage and Microglia Infection with Rapid Turnover of Infected Cells. PLoS Pathogens, 2014, 10, e1004467.	4.7	109
92	Modeling the Timing of Antilatency Drug Administration during HIV Treatment. Journal of Virology, 2014, 88, 14050-14056.	3.4	19
93	Increased Stability and Limited Proliferation of CD4 ⁺ Central Memory T Cells Differentiate Nonprogressive Simian Immunodeficiency Virus (SIV) Infection of Sooty Mangabeys from Progressive SIV Infection of Rhesus Macaques. Journal of Virology, 2014, 88, 4533-4542.	3.4	19
94	Effect of Mature Blood-Stage Plasmodium Parasite Sequestration on Pathogen Biomass in Mathematical and <i>In Vivo</i> Models of Malaria. Infection and Immunity, 2014, 82, 212-220.	2.2	26
95	Intracellular Dynamics of HIV Infection. Journal of Virology, 2014, 88, 1113-1124.	3.4	18
96	Rapid Proliferation and Differentiation Impairs the Development of Memory CD8+ T Cells in Early Life. Journal of Immunology, 2014, 193, 177-184.	0.8	66
97	Decreased Growth Rate of P. falciparum Blood Stage Parasitemia With Age in a Holoendemic Population. Journal of Infectious Diseases, 2014, 209, 1136-1143.	4.0	20
98	Epitope Specificity Delimits the Functional Capabilities of Vaccine-Induced CD8 T Cell Populations. Journal of Immunology, 2014, 193, 5626-5636.	0.8	7
99	Tentative first steps to eradicate latent HIV. Lancet HIV, the, 2014, 1, e2-e3.	4.7	1
100	Linking Pig-Tailed Macaque Major Histocompatibility Complex Class I Haplotypes and Cytotoxic T Lymphocyte Escape Mutations in Simian Immunodeficiency Virus Infection. Journal of Virology, 2014, 88, 14310-14325.	3.4	21
101	Fifteen to Twenty Percent of HIV Substitution Mutations Are Associated with Recombination. Journal of Virology, 2014, 88, 3837-3849.	3.4	31
102	Cycling Memory CD4 ⁺ T Cells in HIV Disease Have a Diverse T Cell Receptor Repertoire and a Phenotype Consistent with Bystander Activation. Journal of Virology, 2014, 88, 5369-5380.	3.4	24
103	Identifying Recombination Hot Spots in the HIV-1 Genome. Journal of Virology, 2014, 88, 2891-2902.	3.4	45
104	Insights into the Motif Preference of APOBEC3 Enzymes. PLoS ONE, 2014, 9, e87679.	2.5	23
105	Measuring Turnover of SIV DNA in Resting CD4+ T Cells Using Pyrosequencing: Implications for the Timing of HIV Eradication Therapies. PLoS ONE, 2014, 9, e93330.	2.5	10
106	A spectrum of (avoidable) HIV latency?. Microbiology Australia, 2014, 35, 95.	0.4	0
107	Specificity, promiscuity, and precursor frequency in immunoreceptors. Current Opinion in Immunology, 2013, 25, 639-645.	5.5	17
108	Footprint of APOBEC3 on the Genome of Human Retroelements. Journal of Virology, 2013, 87, 8195-8204.	3.4	31

#	Article	IF	Citations
109	Estimating the contribution of the gut to plasma viral load in early SIV infection. Retrovirology, 2013, 10, 105.	2.0	4
110	Immunogenetics and transplantation. Current Opinion in Immunology, 2013, 25, 606-607.	5.5	0
111	Gammaherpesvirus latency induces antibody-associated thrombocytopenia in mice. Journal of Autoimmunity, 2013, 42, 71-79.	6.5	11
112	NKT and MAIT invariant TCRÎ \pm sequences can be produced efficiently by VJ gene recombination. Immunobiology, 2013, 218, 213-224.	1.9	65
113	The search for an HIV cure: tackling latent infection. Lancet Infectious Diseases, The, 2013, 13, 614-621.	9.1	61
114	Acute Neonatal Infections â€~Lock-In' a Suboptimal CD8+ T Cell Repertoire with Impaired Recall Responses. PLoS Pathogens, 2013, 9, e1003572.	4.7	27
115	Trivalent Live Attenuated Influenza-Simian Immunodeficiency Virus Vaccines: Efficacy and Evolution of Cytotoxic T Lymphocyte Escape in Macaques. Journal of Virology, 2013, 87, 4146-4160.	3.4	17
116	Estimating Cytomegalovirus Growth Rates by Using Only a Single Point. Journal of Virology, 2013, 87, 3376-3381.	3.4	9
117	Density-Dependent Blood Stage Plasmodium falciparum Suppresses Malaria Super-Infection in a Malaria Holoendemic Population. American Journal of Tropical Medicine and Hygiene, 2013, 89, 850-856.	1.4	6
118	Standard Trivalent Influenza Virus Protein Vaccination Does Not Prime Antibody-Dependent Cellular Cytotoxicity in Macaques. Journal of Virology, 2013, 87, 13706-13718.	3.4	41
119	Where Have All the Parasites Gone? Modelling Early Malaria Parasite Sequestration Dynamics. PLoS ONE, 2013, 8, e55961.	2.5	9
120	Clinical Assessment of Anti-Viral CD8+ T Cell Immune Monitoring Using QuantiFERON-CMV® Assay to Identify High Risk Allogeneic Hematopoietic Stem Cell Transplant Patients with CMV Infection Complications. PLoS ONE, 2013, 8, e74744.	2.5	78
121	Use it or lose it: establishment and persistence of T cell memory. Frontiers in Immunology, 2012, 3, 357.	4.8	35
122	Lifelong Persistent Viral Infection Alters the Naive T Cell Pool, Impairing CD8 T Cell Immunity in Late Life. Journal of Immunology, 2012, 189, 5356-5366.	0.8	79
123	An "Escape Clock―for Estimating the Turnover of SIV DNA in Resting CD4+ T Cells. PLoS Pathogens, 2012, 8, e1002615.	4.7	21
124	The Dynamics of Naturally Acquired Immunity to Plasmodium falciparum Infection. PLoS Computational Biology, 2012, 8, e1002729.	3.2	46
125	Consequences of suboptimal priming are apparent for lowâ€avidity Tâ€cell responses. Immunology and Cell Biology, 2012, 90, 216-223.	2.3	8
126	Early Priming Minimizes the Age-Related Immune Compromise of CD8+ T Cell Diversity and Function. PLoS Pathogens, 2012, 8, e1002544.	4.7	60

#	Article	IF	CITATIONS
127	DNAzyme Targeting c- <i>jun</i> Suppresses Skin Cancer Growth. Science Translational Medicine, 2012, 4, 139ra82.	12.4	60
128	The origin of genetic diversity in HIV-1. Virus Research, 2012, 169, 415-429.	2.2	110
129	APOBEC3G and APOBEC3F rarely co-mutate the same HIV genome. Retrovirology, 2012, 9, 113.	2.0	17
130	Mining the mechanisms of an HIV vaccine. Nature Medicine, 2012, 18, 1020-1021.	30.7	3
131	Simian-Human Immunodeficiency Infection – Is the Course Set in the Acute Phase?. PLoS ONE, 2011, 6, e17180.	2.5	2
132	Escape from highly effective public CD8+ T-cell clonotypes by HIV. Blood, 2011, 118, 2138-2149.	1.4	103
133	APOBEC3 Has Not Left an Evolutionary Footprint on the HIV-1 Genome. Journal of Virology, 2011, 85, 9139-9146.	3.4	27
134	Nonrandom attrition of the naive CD8 ⁺ T-cell pool with aging governed by T-cell receptor:pMHC interactions. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 13694-13699.	7.1	125
135	HIV Immune Escape at an Immunodominant Epitope in HLA-B*27–Positive Individuals Predicts Viral Load Outcome. Journal of Immunology, 2011, 186, 479-488.	0.8	31
136	Evolution of the Antigen-Specific CD8+ TCR Repertoire across the Life Span: Evidence for Clonal Homogenization of the Old TCR Repertoire. Journal of Immunology, 2011, 186, 2056-2064.	0.8	68
137	A Mechanism for TCR Sharing between T Cell Subsets and Individuals Revealed by Pyrosequencing. Journal of Immunology, 2011, 186, 4285-4294.	0.8	194
138	Comparing the Kinetics of NK Cells, CD4, and CD8 T Cells in Murine Cytomegalovirus Infection. Journal of Immunology, 2011, 187, 1385-1392.	0.8	35
139	Persistent Survival of Prevalent Clonotypes within an Immunodominant HIV Gag-Specific CD8+ T Cell Response. Journal of Immunology, 2011, 186, 359-371.	0.8	40
140	Low levels of SIV infection in sooty mangabey central memory CD4+ T cells are associated with limited CCR5 expression. Nature Medicine, 2011, 17, 830-836.	30.7	206
141	Drug-induced thrombocytopenia: development of a novel NOD/SCID mouse model to evaluate clearance of circulating platelets by drug-dependent antibodies and the efficacy of IVIG. Blood, 2010, 116, 1958-1960.	1.4	18
142	Cell-autonomous and environmental contributions to the interstitial migration of T cells. Seminars in Immunopathology, 2010, 32, 257-274.	6.1	53
143	A novel fluorescent-based assay reveals that thrombopoietin signaling and Bcl-XL influence, respectively, platelet and erythrocyte lifespans. Experimental Hematology, 2010, 38, 453-461.e1.	0.4	15
144	Diversity and clonotypic composition of influenzaâ€specific CD8 ⁺ TCR repertoires remain unaltered in the absence of Aire. European Journal of Immunology, 2010, 40, 849-858.	2.9	6

#	Article	IF	Citations
145	Predicting CD62L expression during the CD8 ⁺ Tâ€eell response <i>in vivo</i> . Immunology and Cell Biology, 2010, 88, 157-164.	2.3	29
146	Timing of Immune Escape Linked to Success or Failure of Vaccination. PLoS ONE, 2010, 5, e12774.	2.5	13
147	Vaccination-Induced Noncytolytic Effects in the Acute Phase of SHIV Infection. PLoS ONE, 2010, 5, e15083.	2.5	5
148	Biological Determinants of Immune Reconstitution in HIVâ€Infected Patients Receiving Antiretroviral Therapy: The Role of Interleukin 7 and Interleukin 7 Receptor α and Microbial Translocation. Journal of Infectious Diseases, 2010, 202, 1254-1264.	4.0	109
149	Limited CD4+ T cell proliferation leads to preservation of CD4+ T cell counts in SIV-infected sooty mangabeys. Proceedings of the Royal Society B: Biological Sciences, 2010, 277, 3773-3781.	2.6	24
150	Does Cytolysis by CD8+ T Cells Drive Immune Escape in HIV Infection?. Journal of Immunology, 2010, 185, 5093-5101.	0.8	30
151	Diversity of the CD8+ T Cell Repertoire Elicited against an Immunodominant Epitope Does Not Depend on the Context of Infection. Journal of Immunology, 2010, 184, 2958-2965.	0.8	20
152	Convergent recombination shapes the clonotypic landscape of the na \tilde{A} -ve T-cell repertoire. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 19414-19419.	7.1	131
153	Accurately Measuring Recombination between Closely Related HIV-1 Genomes. PLoS Computational Biology, 2010, 6, e1000766.	3.2	51
154	Genetic and Structural Basis for Selection of a Ubiquitous T Cell Receptor Deployed in Epstein-Barr Virus Infection. PLoS Pathogens, 2010, 6, e1001198.	4.7	110
155	CD8+ T Cell Control of HIV—A Known Unknown. PLoS Pathogens, 2010, 6, e1000728.	4.7	25
156	Reducing chimera formation during PCR amplification to ensure accurate genotyping. Gene, 2010, 469, 45-51.	2.2	90
157	Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection. Journal of Experimental Medicine, 2009, 206, 923-936.	8.5	140
158	Kinetics of Major Histocompatibility Class I Antigen Presentation in Acute Infection. Journal of Immunology, 2009, 182, 902-911.	0.8	5
159	Complexity of the Inoculum Determines the Rate of Reversion of SIV Gag CD8 T Cell Mutant Virus and Outcome of Infection. PLoS Pathogens, 2009, 5, e1000378.	4.7	10
160	Is the Gut the Major Source of Virus in Early Simian Immunodeficiency Virus Infection?. Journal of Virology, 2009, 83, 7517-7523.	3.4	23
161	Divisionâ€linked differentiation can account for CD8 ⁺ Tâ€cell phenotype <i>in vivo</i> . European Journal of Immunology, 2009, 39, 67-77.	2.9	21
162	Extraction and characterization of the rhesus macaque Tâ€eell receptor βâ€chain genes. Immunology and Cell Biology, 2009, 87, 546-553.	2.3	25

#	Article	IF	CITATIONS
163	Low red cell production may protect against severe anemia during a malaria infection—Insights from modeling. Journal of Theoretical Biology, 2009, 257, 533-542.	1.7	28
164	Narrowed TCR diversity for immunised mice challenged with recombinant influenza A-HIV Env311–320 virus. Vaccine, 2009, 27, 6755-6761.	3.8	11
165	The race between infection and immunity: how do pathogens set the pace?. Trends in Immunology, 2009, 30, 61-66.	6.8	31
166	Infectious diseases: Too little, too late for tuberculosis. Immunology and Cell Biology, 2008, 86, 293-294.	2.3	5
167	The molecular basis for public T-cell responses?. Nature Reviews Immunology, 2008, 8, 231-238.	22.7	324
168	The effect of early versus delayed challenge after vaccination in controlling SHIV 89.6P infection. Virology, 2008, 381, 75-80.	2.4	2
169	Method for assessing the similarity between subsets of the T cell receptor repertoire. Journal of Immunological Methods, 2008, 329, 67-80.	1.4	67
170	Rates of HIV immune escape and reversion: implications for vaccination. Trends in Microbiology, 2008, 16, 561-566.	7.7	53
171	TCR Î ² -Chain Sharing in Human CD8+ T Cell Responses to Cytomegalovirus and EBV. Journal of Immunology, 2008, 181, 7853-7862.	0.8	124
172	Limited Maintenance of Vaccine-Induced Simian Immunodeficiency Virus-Specific CD8 T-Cell Receptor Clonotypes after Virus Challenge. Journal of Virology, 2008, 82, 7357-7368.	3.4	13
173	Terminal Deoxynucleotidyltransferase Is Required for the Establishment of Private Virus-Specific CD8+ TCR Repertoires and Facilitates Optimal CTL Responses. Journal of Immunology, 2008, 181, 2556-2562.	0.8	23
174	The Role of Production Frequency in the Sharing of Simian Immunodeficiency Virus-Specific CD8+TCRs between Macaques. Journal of Immunology, 2008, 181, 2597-2609.	0.8	40
175	Estimating the Impact of Vaccination on Acute Simian-Human Immunodeficiency Virus/Simian Immunodeficiency Virus Infections. Journal of Virology, 2008, 82, 11589-11598.	3.4	15
176	Vaccination and Timing Influence SIV Immune Escape Viral Dynamics In Vivo. PLoS Pathogens, 2008, 4, e12.	4.7	43
177	CD4+ Target Cell Availability Determines the Dynamics of Immune Escape and Reversion In Vivo. Journal of Virology, 2008, 82, 4091-4101.	3.4	21
178	Homogenization of TCR Repertoires within Secondary CD62Lhigh and CD62Llow Virus-Specific CD8+ T Cell Populations. Journal of Immunology, 2008, 180, 7938-7947.	0.8	13
179	Killer T cells regulate antigen presentation for early expansion of memory, but not naive, CD8+ T cell. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 6341-6346.	7.1	49
180	Symptomatic and Asymptomatic Viral Recrudescence in Solid-Organ Transplant Recipients and Its Relationship with the Antigen-Specific CD8 ⁺ T-Cell Response. Journal of Virology, 2007, 81, 11538-11542.	3.4	40

#	Article	IF	Citations
181	Comparative Efficacy of Subtype AE Simian-Human Immunodeficiency Virus Priming and Boosting Vaccines in Pigtail Macaques. Journal of Virology, 2007, 81, 292-300.	3.4	48
182	A kinetic model of bone marrow neutrophil production that characterizes late phenotypic maturation. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 292, R1707-R1716.	1.8	25
183	In Vivo Fitness Costs of Different Gag CD8 T-Cell Escape Mutant Simian-Human Immunodeficiency Viruses for Macaques. Journal of Virology, 2007, 81, 5418-5422.	3.4	29
184	Vaccine-Induced T Cells Control Reversion of AIDS Virus Immune Escape Mutants. Journal of Virology, 2007, 81, 4137-4144.	3.4	34
185	Estimating the Infectivity of CCR5-Tropic Simian Immunodeficiency Virus SIV mac251 in the Gut. Journal of Virology, 2007, 81, 8025-8029.	3.4	16
186	The T cell repertoire in infection and vaccination: implications for control of persistent viruses. Current Opinion in Immunology, 2007, 19, 294-300.	5.5	63
187	Understanding the mechanisms and limitations of immune control of HIV. Immunological Reviews, 2007, 216, 164-175.	6.0	44
188	Methods for comparing the diversity of samples of the T cell receptor repertoire. Journal of Immunological Methods, 2007, 321, 182-195.	1.4	181
189	Validation of RNA-based molecular clonotype analysis for virus-specific CD8+ T-cells in formaldehyde-fixed specimens isolated from peripheral blood. Journal of Immunological Methods, 2007, 326, 127-138.	1.4	7
190	Sequential Broadening of CTL Responses in Early HIV-1 Infection Is Associated with Viral Escape. PLoS ONE, 2007, 2, e225.	2.5	68
191	Preferential invasion of reticulocytes during late-stage Plasmodium berghei infection accounts for reduced circulating reticulocyte levels. International Journal for Parasitology, 2006, 36, 1389-1397.	3.1	69
192	Influence of Peak Viral Load on the Extent of CD4+ T-Cell Depletion in Simian HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 259-265.	2.1	37
193	Sharing of T cell receptors in antigen-specific responses is driven by convergent recombination. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18691-18696.	7.1	222
194	Nail`ve and Memory Cell Turnover as Drivers of CCR5-to-CXCR4 Tropism Switch in Human Immunodeficiency Virus Type 1: Implications for Therapy. Journal of Virology, 2006, 80, 802-809.	3.4	73
195	A virus-specific CD8+ T cell immunodominance hierarchy determined by antigen dose and precursor frequencies. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 994-999.	7.1	149
196	Early establishment of diverse T cell receptor profiles for influenza-specific CD8+CD62Lhi memory T cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9184-9189.	7.1	79
197	The pigtail macaque MHC class I alleleMane-A*10presents an immundominant SIV Gag epitope: identification, tetramer development and implications of immune escape and reversion. Journal of Medical Primatology, 2005, 34, 282-293.	0.6	45
198	Contemporaneous fluctuations in T?cell responses to persistent herpes virus infections. European Journal of Immunology, 2005, 35, 139-149.	2.9	32

#	Article	IF	Citations
199	The effects of thymic selection on the range of T cell cross-reactivity. European Journal of Immunology, 2005, 35, 3452-3459.	2.9	27
200	Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. Hepatology, 2005, 41, 1383-1390.	7.3	125
201	Contribution of T cell receptor affinity to overall avidity for virus-specific CD8+ T cell responses. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11432-11437.	7.1	58
202	High-Potency Human Immunodeficiency Virus Vaccination Leads to Delayed and Reduced CD8 + T-Cell Expansion but Improved Virus Control. Journal of Virology, 2005, 79, 10059-10062.	3.4	28
203	Rapid Viral Escape at an Immunodominant Simian-Human Immunodeficiency Virus Cytotoxic T-Lymphocyte Epitope Exacts a Dramatic Fitness Cost. Journal of Virology, 2005, 79, 5721-5731.	3.4	164
204	Reversion of immune escape HIV variants upon transmission: insights into effective viral immunity. Trends in Microbiology, 2005, 13, 243-246.	7.7	39
205	Effects of Antibody on Viral Kinetics in Simian/Human Immunodeficiency Virus Infection: Implications for Vaccination. Journal of Virology, 2004, 78, 5520-5522.	3.4	23
206	Predicting the Impact of a Nonsterilizing Vaccine against Human Immunodeficiency Virus. Journal of Virology, 2004, 78, 11340-11351.	3.4	61
207	Kinetics of Virus-Specific CD8 + T Cells and the Control of Human Immunodeficiency Virus Infection. Journal of Virology, 2004, 78, 10096-10103.	3.4	105
208	Modelling the impact of antigen kinetics on Tâ€cell activation and response. Immunology and Cell Biology, 2004, 82, 55-61.	2.3	10
209	A stochastic model of cytotoxic T cell responses. Journal of Theoretical Biology, 2004, 228, 227-240.	1.7	91
210	Naive T cells are maintained by thymic output in early ages but by proliferation without phenotypic change after age twenty. Immunology and Cell Biology, 2003, 81, 487-495.	2.3	99
211	Clonal Selection, Clonal Senescence, and Clonal Succession: The Evolution of the T Cell Response to Infection with a Persistent Virus. Journal of Immunology, 2002, 168, 3309-3317.	0.8	89
212	Cell turnover and cell tropism in HIV-1 infection. Trends in Microbiology, 2002, 10, 275-278.	7.7	29
213	Rapid disease progression and the rate of spread of the HIV epidemic. Aids, 2001, 15, 2055-2057.	2.2	1
214	A homing selection hypothesis for T-cell trafficking. Trends in Immunology, 2000, 21, 315-317.	7.5	31
215	Benefits of memory. Nature Immunology, 2000, 1, 451-451.	14.5	2
216	HIV-1 Variation Diminishes CD4 T Lymphocyte Recognition. Journal of Experimental Medicine, 1998, 188, 1785-1793.	8.5	67

#	ARTICLE	IF	CITATIONS
217	HLA Class I Binding Motifs Derived from Random Peptide Libraries Differ at the COOH Terminus from Those of Eluted Peptides. Journal of Experimental Medicine, 1997, 185, 367-372.	8.5	46
218	Reverse immunogenetics: from HLA-disease associations to vaccine candidates. Trends in Molecular Medicine, 1996, 2, 38-45.	2.6	63
219	The MHC in Host-Pathogen Evolution. , 1996, , 243-260.		0
220	Antagonists or altruists: do viral mutants modulate T-cell responses?. Trends in Immunology, 1995, 16, 432-436.	7. 5	26
221	Interactions between <i>Plasmodium falciparum</i> and HLA molecules. Biochemical Society Transactions, 1994, 22, 282-285.	3.4	7
222	Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature, 0, , .	27.8	104